InvestorsHub Logo
icon url

Whalatane

10/28/20 6:03 PM

#235328 RE: biocqr #235326

Looks like Gr8 data. Thx for the link . Are the issue .... limited doses available , difficult to scale and expensive ?
Kiwi
icon url

DewDiligence

10/29/20 3:08 PM

#235343 RE: biocqr #235326

REGN:

https://www.prnewswire.com/news-releases/regeneron-once-again-earns-1-ranking-in-science-magazines-top-biopharma-companies-to-work-for-301163300.html

Regeneron Pharmaceuticals, Inc. today announced that the company was once again ranked as the top company to work for by Science magazine in its annual Top Employers Survey of the global biotech and pharmaceutical industry. Regeneron has placed either first or second for the past ten years, making it the most highly ranked company of the decade. This year, Regeneron placed first based on more than 7,650 responses from people across the industry and stood out with particularly high marks on measures of innovation, being socially responsible and loyal employees.

Quite impressive. Genentech was a frequent winner of this award back in the day, if I recall correctly. Related tidbit: #msg-16127025.
icon url

biocqr

10/29/20 8:32 PM

#235350 RE: biocqr #235326

CMS guidance on administering COVID mAbs...

https://www.cms.gov/files/document/03092020-covid-19-faqs-508.pdf

Pg 121...

Question: CMS has established flexibilities under the Hospital Without Walls initiative to allow hospitals to furnish care in temporary expansion sites, including erected tents, retrofitted convention centers and beneficiaries’ homes. Would hospitals also be able to use these same flexibilities to furnish monoclonal antibodies in temporary expansion sites?

Answer: In response to the COVID-19 Public Health Emergency (PHE), CMS issued several 1135 waivers of certain hospital conditions of participation and the provider-based rules, in order to allow hospitals to furnish hospital services, including drug administration, in temporary expansion sites. These Hospital Without Walls flexibilities could be used by hospitals to furnish monoclonal antibodies in temporary expansion sites, such as an erected tent, a retrofitted convention center, or the beneficiary’s home, consistent with the terms of the EUA or FDA approval, as applicable. Hospitals that previously constructed expansion sites at the beginning of the PHE, and were approved under earlier 1135 waivers, are able to continue using those sites so long that they continue to meet the conditions of participation that remain in effect during the COVID-19 PHE.

Further, as previously announced in the April 30, 2020 Interim Final Rule (85 FR 27559-62), hospitals that temporarily relocate an existing on-campus or excepted off-campus provider based department in order to furnish outpatient care in a temporary expansion site may
wish to submit a temporary relocation exception request to their Regional Office, which would enable them to continue to be paid under the Outpatient Prospective Payment System for services furnished at the relocated department. More information about the Hospitals Without Walls flexibilities and the temporary extraordinary circumstances relocation exception can be found here.
New: 10/28/20